Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 11/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305581 | 0.85 | JAK2 (0.38) | LCKBRAFKDRMAPK14JAK2 | |
| SCHEMBL3304641 | 0.83 | MAPK14 (0.39) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL2145136 | 0.82 | JAK2 (0.39) | LCKBRAFKDRMAPK14JAK2 | |
| SCHEMBL3302102 | 0.81 | JAK2 (0.47) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL3299822 | 0.81 | SYK (0.40) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL3302942 | 0.80 | SYK (0.42) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL3305434 | 0.80 | JAK2 (0.37) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL2144402 | 0.79 | JAK2 (0.37) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL3303709 | 0.79 | SYK (0.41) | LCKBRAFKDRMAPK14SYK | |
| SCHEMBL3300617 | 0.78 | JAK2 (0.42) | LCKBRAFKDRMAPK14SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | LCK 59/4885BRAF 151/4885KDR 1041/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | LCK 59/4885BRAF 151/4885KDR 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.